GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
GE Healthcare warned European providers Feb. 7 to discontinue the use of gadodiamide (Omniscan) for patients who may be at risk for a rare and life-threatening skin disease.
Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, may occur in patients with moderate to end-stage kidney disease after an MRI or MR angiography study with gadolinium-based contrast media. NSF causes problems in the joints and in some cases quickly results in loss of mobility or death.
The manufacturer's warning is associated with a new ruling from the European Medicines Agency, the regulatory body for pharmaceuticals in the European Union. The EMEA decision was also released Feb. 7.
In line with the EMEA alert, GE advises that Omniscan is contraindicated in the following cases:
The manufacturer also advised caution when administering gadodiamide to neonates and infants up to one year old, again in line with EMEA guidance.
As of Feb.7, GE had received 96 reports of NSF following Omniscan administration. In most cases, high doses were administered. Although regulatory agencies have received reports of NSF following administration of other gadolinium-based MR agents, most have been linked to Omniscan, according to GE.
The company advised physicians to use general radiography and other alternative imaging techniques for patients with severely compromised renal function. Physicians can call the following numbers if they have questions or to report cases:
For more information from the Diagnostic Imaging archives:
European authorities warn against use of Omniscan in at-risk patients
FDA renews warning on gadolinium in patients with weak kidneys
Gadolinium-related problems stem from one specific agent
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.